aTyr Pharma Croissance future

Future contrôle des critères 5/6

aTyr Pharma devrait augmenter ses bénéfices et ses revenus de 62.5% et de 80.2% par an respectivement, tandis que le BPA devrait croître de croître de 63% par an.

Informations clés

62.5%

Taux de croissance des bénéfices

63.0%

Taux de croissance du BPA

Biotechs croissance des bénéfices	28.3%
Taux de croissance des recettes	80.2%
Rendement futur des capitaux propres	n/a
Couverture par les analystes	Good
Dernière mise à jour	18 Nov 2024

Mises à jour récentes de la croissance future

Recent updates

Here's Why We're Not Too Worried About aTyr Pharma's (NASDAQ:LIFE) Cash Burn Situation

Oct 04

Here's Why We're Watching aTyr Pharma's (NASDAQ:LIFE) Cash Burn Situation

May 06

We're Keeping An Eye On aTyr Pharma's (NASDAQ:LIFE) Cash Burn Rate

Jan 04

aTyr Pharma rises on U.S. patent for anti-neuropilin-2 monoclonal antibodies

Sep 29

aTyr Pharma stock rises on FDA fast track status for efzofitimod for lung disease

Sep 13

aTyr Pharma gains with FDA Fast Track status for lead asset

Aug 11

We Think aTyr Pharma (NASDAQ:LIFE) Needs To Drive Business Growth Carefully

May 10

Is aTyr Pharma (NASDAQ:LIFE) In A Good Position To Deliver On Growth Plans?

Jan 24

aTyr Pharma: Successful Proof Of Concept In Pulmonary Sarcoidosis

Dec 28

aTyr Stock Is Buoyant On Highly-Promising Lung Disease Data - Wait For Hype To Die Down And Buy

Sep 24

Is aTyr Pharma (NASDAQ:LIFE) In A Good Position To Deliver On Growth Plans?

Sep 23

Is aTyr Pharma (NASDAQ:LIFE) In A Good Position To Deliver On Growth Plans?

May 22

aTyr Pharma, Inc. (NASDAQ:LIFE) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

Mar 25

Did You Miss aTyr Pharma's (NASDAQ:LIFE) Impressive 103% Share Price Gain?

Feb 09

aTyr Pharma, Kyorin concludes subject visits for early-stage ATYR1923 trial in Japan

Jan 14

ATyr Pharma's lead candidate meets safety endpoint in COVID-19 study

Jan 04

aTyr Pharma concludes enrollment in mid-stage inflammatory lung diseases study

Dec 21

aTyr Pharma (LIFE) Investor Presentation - Slideshow

Oct 31

Prévisions de croissance des bénéfices et des revenus

NasdaqCM:ATYR - Estimations futures des analystes et données financières antérieures (USD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2026	43	-60	-65	-145	7
12/31/2025	4	-68	-57	-58	7
12/31/2024	0	-67	-58	-76	6
9/30/2024	0	-64	-67	-67	N/A
6/30/2024	1	-58	-64	-63	N/A
3/31/2024	1	-54	-58	-55	N/A
12/31/2023	0	-50	-37	-33	N/A
9/30/2023	11	-43	-38	-33	N/A
6/30/2023	10	-45	-40	-35	N/A
3/31/2023	10	-45	-35	-32	N/A
12/31/2022	10	-45	-44	-42	N/A
9/30/2022	N/A	-46	-40	-40	N/A
6/30/2022	N/A	-41	-39	-39	N/A
3/31/2022	N/A	-39	-38	-37	N/A
12/31/2021	N/A	-34	-33	-33	N/A
9/30/2021	2	-30	-31	-30	N/A
6/30/2021	2	-29	-25	-24	N/A
3/31/2021	2	-25	-23	-23	N/A
12/31/2020	10	-16	-16	-15	N/A
9/30/2020	9	-17	-15	-15	N/A
6/30/2020	9	-16	-14	-14	N/A
3/31/2020	8	-16	-12	-12	N/A
12/31/2019	0	-24	-20	-20	N/A
9/30/2019	0	-24	-20	-20	N/A
6/30/2019	0	-25	-22	-22	N/A
3/31/2019	N/A	-30	-27	-27	N/A
12/31/2018	N/A	-35	-32	-31	N/A
9/30/2018	N/A	-40	-37	-37	N/A
6/30/2018	N/A	-44	N/A	-39	N/A
3/31/2018	N/A	-45	N/A	-39	N/A
12/31/2017	N/A	-48	N/A	-42	N/A
9/30/2017	N/A	-49	N/A	-44	N/A
6/30/2017	N/A	-52	N/A	-50	N/A
3/31/2017	N/A	-55	N/A	-54	N/A
12/31/2016	N/A	-58	N/A	-53	N/A
9/30/2016	N/A	-62	N/A	-51	N/A
6/30/2016	N/A	-59	N/A	-46	N/A
3/31/2016	N/A	-55	N/A	-43	N/A
12/31/2015	N/A	-48	N/A	-37	N/A
9/30/2015	N/A	-38	N/A	-33	N/A
6/30/2015	N/A	-33	N/A	-29	N/A
3/31/2015	N/A	-28	N/A	-23	N/A
12/31/2014	N/A	-25	N/A	-23	N/A
9/30/2014	N/A	-24	N/A	-21	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: ATYR devrait devenir rentable au cours des 3 prochaines années, ce qui est considéré comme une croissance plus rapide que le taux d'épargne ( 2.6% ).

Bénéfices vs marché: ATYR devrait devenir rentable au cours des 3 prochaines années, ce qui est considéré comme une croissance supérieure à la moyenne du marché.

Croissance élevée des bénéfices: ATYR devrait devenir rentable dans les 3 prochaines années.

Chiffre d'affaires vs marché: Le chiffre d'affaires de ATYR ( 80.2% par an) devrait croître plus rapidement que le marché US ( 8.9% par an).

Croissance élevée des revenus: Le chiffre d'affaires de ATYR ( 80.2% par an) devrait croître plus rapidement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de ATYR devrait être élevé dans 3 ans

aTyr Pharma Croissance future

Future contrôle des critères 5/6

Informations clés

Mises à jour récentes de la croissance future

Price target increased by 8.8% to US$24.60

Consensus revenue estimates decrease by 85%, EPS upgraded

Consensus revenue estimates fall by 70%

Forecast to breakeven in 2026

Consensus revenue estimates fall by 93%

Consensus EPS estimates upgraded to US$0.90 loss

Recent updates

New minor risk - Financial position

New minor risk - Profitability

aTyr Pharma: Two 2025 Data Readouts Could Provide Inflection Point

New minor risk - Share price stability

Independent Director recently bought US$185k worth of stock

aTyr Pharma, Inc. Completes Enrollment in Global Pivotal Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis

We Think aTyr Pharma (NASDAQ:ATYR) Needs To Drive Business Growth Carefully

Independent Chairman of the Board recently bought US$88k worth of stock

Price target increased by 8.8% to US$24.60

aTyr Pharma, Inc. Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis

Consensus revenue estimates decrease by 85%, EPS upgraded

aTyr Pharma, Inc., Annual General Meeting, May 22, 2024

Consensus revenue estimates fall by 70%

New minor risk - Profitability

New major risk - Revenue size

Forecast to breakeven in 2026

aTyr Pharma, Inc. to Report Q4, 2023 Results on Mar 14, 2024

aTyr Pharma, Inc. Announces Plans to Initiate an Individual Patient Expanded Access Program for Its Lead Therapeutic Candidate, Efzofitimod, for Patients with Pulmonary Sarcoidosis

We're Hopeful That aTyr Pharma (NASDAQ:LIFE) Will Use Its Cash Wisely

Consensus revenue estimates fall by 93%

Atyr Pharma, Inc. Announces Dosing of First Patient in Phase 2 Efzo-Connect™? Study of Efzofitimod in Patients with Ssc-Ild

Here's Why We're Not Too Worried About aTyr Pharma's (NASDAQ:LIFE) Cash Burn Situation

Atyr Pharma Presents Efzofitimod Data Demonstrating Statistically Significant Improvements in Time to Relapse, Fvc and Patient Reported Outcomes

Consensus EPS estimates upgraded to US$0.90 loss

Price target increased by 17% to US$23.25

Consensus EPS estimates upgraded to US$1.03 loss

Independent Director recently bought US$450k worth of stock

Here's Why We're Watching aTyr Pharma's (NASDAQ:LIFE) Cash Burn Situation

Consensus revenue estimates fall by 25%

Price target increased by 8.9% to US$22.00

Consensus revenue estimates decrease by 25%

We're Keeping An Eye On aTyr Pharma's (NASDAQ:LIFE) Cash Burn Rate

Consensus forecasts updated

Price target decreased to US$21.20

Insufficient new directors

aTyr Pharma, Inc. Announces Publication of Positive Data from Phase 1B/2A Clinical Study of Efzofitimod for the Treatment of Pulmonary Sarcoidosis in the Journal Chest

aTyr Pharma, Inc. to Report Q3, 2022 Results on Nov 10, 2022

aTyr Pharma rises on U.S. patent for anti-neuropilin-2 monoclonal antibodies

aTyr Pharma, Inc. Announces Dosing of First Patient in Pivotal Phase 3 Efzo-Fit™ Study of Efzofitimod in Patients with Pulmonary Sarcoidosis

Consensus revenue estimates fall by 67%

aTyr Pharma stock rises on FDA fast track status for efzofitimod for lung disease

aTyr Pharma, Inc. Receives FDA Fast Track Designation for Efzofitimod (ATYR1923) for Treatment of Pulmonary Sarcoidosis

aTyr Pharma gains with FDA Fast Track status for lead asset

aTyr Pharma, Inc. to Report Q2, 2022 Results on Aug 15, 2022

Price target decreased to US$17.33

Atyr Pharma, Inc. Announces Phase 3 Study Evaluating the Efficacy and Safety of Its Lead Therapeutic Candidate, efzofitimod

Consensus revenue estimates fall by 33%

We Think aTyr Pharma (NASDAQ:LIFE) Needs To Drive Business Growth Carefully

aTyr Pharma, Inc. to Report Q1, 2022 Results on May 09, 2022

Insufficient new directors

aTyr Pharma to Present Clinical Data for Efzofitimod (ATYR1923) at the American Thoracic Society 2022 International Conference

Full year 2021 earnings: EPS and revenues miss analyst expectations

Consensus forecasts updated

Is aTyr Pharma (NASDAQ:LIFE) In A Good Position To Deliver On Growth Plans?

aTyr Pharma, Inc. Advances Development of Lead Therapeutic Candidate ATYR1923 with Announcement of “efzofitimod” as Nonproprietary Name

aTyr Pharma: Successful Proof Of Concept In Pulmonary Sarcoidosis

Third quarter 2021 earnings released: US$0.42 loss per share (vs US$0.68 loss in 3Q 2020)

aTyr Stock Is Buoyant On Highly-Promising Lung Disease Data - Wait For Hype To Die Down And Buy

Is aTyr Pharma (NASDAQ:LIFE) In A Good Position To Deliver On Growth Plans?

aTyr Pharma, Inc. Announces Positive Data from Phase 1B/2A Clinical Trial Demonstrating Consistent Dose Response for Atyr1923 in Pulmonary Sarcoidosis

Price target increased to US$19.25

Consensus forecasts updated

Is aTyr Pharma (NASDAQ:LIFE) In A Good Position To Deliver On Growth Plans?

Independent Director recently bought US$199k worth of stock

Consensus forecasts updated

Price target increased to US$17.67

aTyr Pharma, Inc. (NASDAQ:LIFE) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

Full year 2020 earnings released: US$1.77 loss per share (vs US$7.03 loss in FY 2019)

aTyr Pharma, Inc. to Report Q4, 2020 Results on Mar 23, 2021